Johnson & Johnson has announced that surgeons have now implanted its Tecnis PureSee intraocular lens (IOL) in 100,000 eyes across Australia and New Zealand.
“This ANZ milestone reflects the confidence established by the Tecnis platform when treating cataract patients over the past 25 years,” the company said.
Johnson & Johnson said the “rapid adoption” of Tecnis Puresee across the region “reflects the confidence ophthalmologists have in the Tecnis platform and their growing focus on delivering visual outcomes that support modern patient lifestyles”.
“Patients no longer judge success solely by whether the cataract is removed; they increasingly expect personalised visual outcomes that support independence, digital lifestyles, night driving, hobbies and reduced reliance on glasses,” the company said.
The Tecnis Portfolio
PureSee is a refractive extended depth of focus (EDOF) lens designed to provide distance and intermediate vision, with some near vision.
It is one of several options in the Tecnis portfolio, alongside monofocal, enhanced monofocal, and full vision range lenses.
Patients… increasingly expect personalised visual outcomes that support independence, digital lifestyles, night driving, hobbies and reduced reliance on glasses
Johnson & Johnson said the range allows surgeons to consider patients’ visual needs beyond distance vision, including digital device use, night driving and reduced dependence on glasses. The company also pointed to its preloaded delivery system and a consistent A-constant across the Tecnis one-piece IOL range as features intended to simplify planning and surgical workflow.
Blake Thomas, Johnson & Johnson MedTech’s country manager for surgical vision in Australia and New Zealand, thanked the surgeons and practice teams for their support in reaching the milestone. He said technologies such as PureSee could “provide surgeons with additional options to support the visual and lifestyle needs of their patients at the time of cataract surgery”.
Johnson & Johnson introduced the Tecnis Eyhance enhanced monofocal IOL in Australia and New Zealand in 2019, followed by PureSee in mid 2024. It was the first refractive EDOF IOL in the market, Johnson & Johnson said.
The company has described Tecnis as the region’s most widely used IOL platform.
